RPL22 and neoplasm: RPL22’s role as a tumor suppressor is further supported by our observation that monoallelic inactivation or deletion of RPL22 was observed in human T-ALL and associated with reduced survival; RPL22 inactivation has also been observed in a variety of solid tumors, particularly colorectal cancer (CRC) [6–10].